About Exelixis Inc

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on cabozantinib, its wholly owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, COTELLICâ„¢ (cobimetinib), a – more... 

Reviews

Overall

5.0
Based on 1 review
5 stars
4 stars
3 stars
2 stars
1 star
Work/Life Balance
4.0
Compensation/Benefits
5.0
Job Security/Advancement
4.0
Management
5.0
Culture
5.0
Claim this company page
Headquarters
South San Francisco California, United States
Revenue
$21 Million
Links
Exelixis Inc website